Clinical studies have found that the tumor immune microenvironment is altered after receiving EGFR-TKIs targeted therapy, including an increase in CD8+ tumor-infiltrating lymphocytes (TILs) density, TMB, and PD-L1 expression in tumor cells (7, 8). The gene discussed is EGFR; the disease is neoplasm.